European paediatric non-alcoholic fatty liver disease registry (EU-PNAFLD): Design and rationale.
View / Open Files
Authors
Mann, Jake P
Vreugdenhil, Anita
Socha, Piotr
Jańczyk, Wojciech
Baumann, Ulrich
Rajwal, Sanjay
Casswall, Thomas
Marcus, Claude
van Mourik, Indra
Savage, David B
Noble-Jamieson, Gabriele
Lacaille, Florence
Dabbas, Myriam
Dubern, Béatrice
Kelly, Deirdre A
Nobili, Valerio
Anstee, Quentin M
Publication Date
2018-12Journal Title
Contemp Clin Trials
ISSN
1551-7144
Publisher
Elsevier BV
Volume
75
Pages
67-71
Language
eng
Type
Article
Physical Medium
Print-Electronic
Metadata
Show full item recordCitation
Mann, J. P., Vreugdenhil, A., Socha, P., Jańczyk, W., Baumann, U., Rajwal, S., Casswall, T., et al. (2018). European paediatric non-alcoholic fatty liver disease registry (EU-PNAFLD): Design and rationale.. Contemp Clin Trials, 75 67-71. https://doi.org/10.1016/j.cct.2018.11.003
Abstract
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder in children and has the potential to progress to advanced fibrosis/cirrhosis, end-stage liver disease and hepatocellular carcinoma. However, the natural history of the condition is poorly understood and there are no approved treatments. The European Paediatric Non-Alcoholic Fatty Liver Disease Registry (EU-PNAFLD) is a multi-centre registry of paediatric NAFLD that will serve as a prospective, observational, natural history study and provide a tractable back-bone to support recruitment into subsequent interventional trials. Collection of samples into a bio-repository will facilitate translational studies, including genome sequencing and metabolomics. EU-PNAFLD will work closely alongside the existing adult European NAFLD Registry to obtain data on clinical outcomes after 20-30 years. Through an international, well-characterised large-scale cohort, EU-PNAFLD will address the key questions in paediatric NAFLD and benefit patients with the condition.
Keywords
Biomarkers, Cirrhosis, Exome sequencing, Fatty liver, Natural history, Adolescent, Biomarkers, Carcinoma, Hepatocellular, Child, Child, Preschool, Disease Progression, Europe, Humans, Infant, Liver, Liver Cirrhosis, Liver Neoplasms, Metabolomics, Non-alcoholic Fatty Liver Disease, Prospective Studies, Registries, Whole Genome Sequencing
Sponsorship
Funding from institutional grants to SOR & DBS from Wellcome Trust UK, to VN from the European Association for the Study of the Liver (EASL), and to JPM from the Children’'s Liver Disease Foundation (CLDF). QMA is supported by the EPoS (Elucidating Pathways of Steatohepatitis) consortium funded by the Horizon 2020 Framework Program of the European Union under Grant Agreement 634413, an EASL Registry Grant and the Newcastle NIHR Biomedical Research Centre.
Funder references
Wellcome Trust (095515/Z/11/Z)
European Commission Horizon 2020 (H2020) Societal Challenges (634413)
Identifiers
External DOI: https://doi.org/10.1016/j.cct.2018.11.003
This record's URL: https://www.repository.cam.ac.uk/handle/1810/284932
Rights
Licence:
http://www.rioxx.net/licenses/all-rights-reserved
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: support@repository.cam.ac.uk